Vernakalant for the treatment of rapid conversion of recent onset atrial fibrillation = 7 days
Status Suspended
Process STA pre-2018
Referral date 01 May 2011
Topic area
  • Cardiovascular

Scoped within Batch 17

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Kate Moore
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
17 February 2021 Expected publication
13 October 2020 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
24 June 2011 Please note that following on from information received from the manufacturer, regarding the timings of the launch of the product in the UK, NICE has decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance